Erste Asset Management GmbH Makes New $1.25 Million Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Erste Asset Management GmbH bought a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 116,850 shares of the biopharmaceutical company's stock, valued at approximately $1,251,000.

A number of other large investors have also recently made changes to their positions in the stock. Millennium Management LLC raised its holdings in Amicus Therapeutics by 1,758.9% in the second quarter. Millennium Management LLC now owns 1,894,176 shares of the biopharmaceutical company's stock worth $18,790,000 after purchasing an additional 1,792,277 shares in the last quarter. William Blair Investment Management LLC raised its holdings in Amicus Therapeutics by 12.8% in the second quarter. William Blair Investment Management LLC now owns 13,003,363 shares of the biopharmaceutical company's stock worth $128,993,000 after purchasing an additional 1,477,084 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in Amicus Therapeutics by 141.1% in the third quarter. Assenagon Asset Management S.A. now owns 2,037,896 shares of the biopharmaceutical company's stock worth $21,765,000 after purchasing an additional 1,192,489 shares in the last quarter. Squarepoint Ops LLC raised its holdings in Amicus Therapeutics by 159.1% in the second quarter. Squarepoint Ops LLC now owns 650,555 shares of the biopharmaceutical company's stock worth $6,454,000 after purchasing an additional 399,449 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its holdings in Amicus Therapeutics by 14.3% in the second quarter. Massachusetts Financial Services Co. MA now owns 3,020,536 shares of the biopharmaceutical company's stock worth $29,964,000 after purchasing an additional 378,999 shares in the last quarter.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on FOLD shares. Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, November 7th. Bank of America boosted their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a "buy" rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. boosted their price target on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 12th. Jefferies Financial Group initiated coverage on Amicus Therapeutics in a research report on Friday, September 6th. They issued a "buy" rating and a $18.00 target price on the stock. Finally, Morgan Stanley dropped their target price on Amicus Therapeutics from $19.00 to $18.00 and set an "overweight" rating on the stock in a research report on Friday, October 11th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $17.63.

Insider Transactions at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $10.60, for a total transaction of $79,500.00. Following the transaction, the chief executive officer now owns 886,654 shares of the company's stock, valued at $9,398,532.40. The trade was a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In the last 90 days, insiders have sold 30,401 shares of company stock valued at $339,363. Corporate insiders own 2.20% of the company's stock.

Amicus Therapeutics Trading Up 0.7 %

Amicus Therapeutics stock traded up $0.07 during midday trading on Wednesday, reaching $9.86. 1,685,165 shares of the stock traded hands, compared to its average volume of 2,684,374. The company has a 50-day simple moving average of $10.65 and a two-hundred day simple moving average of $10.61. Amicus Therapeutics, Inc. has a 12-month low of $9.02 and a 12-month high of $14.57. The firm has a market cap of $2.95 billion, a PE ratio of -28.79 and a beta of 0.60. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.